CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELLIN 肿瘤细胞治疗研究

← 返回

过继性免疫治疗联合放疗和化疗治疗非小细胞肺癌的临床疗效与安全性综合分析：系统评价与 Meta 分析

英文原题：The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis.

查看英文原题

The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis.

PubMed 2022/06/06（内容时间） Appl Bionics Biomech Q4 · IF 1.7（JCR 2025）

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

非小细胞肺癌地区：中国
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

研究概要

过继性免疫治疗联合微放射治疗可降低 NSCLC 的复发并提高患者生存率，且早期患者可从免疫治疗中获益更显著。

研究思路结论见上方概要

目的

探讨放化疗联合过继性免疫治疗与单纯放化疗在非小细胞肺癌（NSCLC）患者中的疗效差异。

方法

合格的随机对照试验（randomized controlled trial，RCT）或非随机同期对照试验（NRCCT），发表于PubMed、EMBASE、中国期刊全文数据库、Medline、Cochrane数据库和维普中文数据库等多个数据库，并采用Revman5.0软件进行数据分析。

结果

我们发现实验组和对照组之间的疗效有显著差异（OR = 1.94，95% CI（1.46，2.58），P < 0.001，I 2 = 0%，Z = 4.59），过继性免疫治疗对疾病进展的影响（OR = 1.80，95% CI（1.38，2.35），P < 0.001，I 2 = 0%，Z = 4.33），过继性免疫治疗对总生存期的影响（OR = 2.19，95% CI（1.60，2.99），P < 0.001，I 2 = 0%，Z = 4.91），以及过继性免疫治疗的不良反应（OR = 1.76，95% CI（1.25，2.48），P = 0.001，I 2 = 0%，Z = 3.26）。

展开英文摘要原文
OBJECTIVE

To explore the differential efficacy of chemoradiotherapy combined with adoptive immunotherapy and radiochemotherapy alone in patients with non-small-cell lung cancer (NSCLC).

METHODS

Qualified randomized controlled trial (randomized controlled trial, RCT), or nonrandomized concurrent controlled trial (NRCCT), published in various databases, including PubMed, EMBASE, Chinese journal full-text database, Medline, Cochrane database, and VIP Chinese database, and the Revman5. 0 software performed the data analysis.

RESULTS

We found the significantly different curative effect between the experimental and control groups (OR = 1.94, 95% CI (1.46, 2.58), P < 0.001, I 2 = 0%, Z = 4.59), effect of adoptive immunotherapy on the progression of disease (OR = 1.80, 95% CI (1.38, 2.35), P < 0.001, I 2 = 0%, Z = 4.33), adoptive immunotherapy on overall survival (OR = 2.19, 95% CI (1.60, 2.99), P < 0.001, I 2 = 0%, Z = 4.91), and adverse effects of adoptive immunotherapy (OR = 1.76, 95% CI (1.25, 2.48), P = 0.001, I 2 = 0%, Z = 3.26).

CONCLUSION

Adoptive immunotherapy combined with microradiotherapy can decrease the recurrence of NSCLC and improve patient survival, as well as early patients can be benefited more significantly from immunotherapy.

论文信息

作者
Fan Z、He H、Chen L
单位
Departments of Oncology, The First Naval Hospital of Southern Theater of People's Liberation Army, Zhanjiang, Guangdong, China.China
文献类型
已撤稿
期刊
Applied bionics and biomechanics2022
原文标识
PubMed 35706510　·　DOI 10.1155/2022/2731744

在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →